Osteoporosis in older persons: Current pharmacotherapy and future directions

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 14, 2013, Pages 1949-1958

  Duque, Gustavo ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Alendronate; Anabolics; Anti resorptives; Bisphosphonates; Bone biomarkers; Bone mineral density; Cathepsin K; Denosumab; Elderly; Fractures; Older persons; Osteoblast; Osteoclast; Osteoporosis; Risedronate; Sclerostin; Teriparatide

Indexed keywords

ALENDRONIC ACID; CALCIUM; CATHEPSIN K; COLONY STIMULATING FACTOR 1; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DENOSUMAB; ESTRADIOL; ESTROGEN; IBANDRONIC ACID; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 6; MONOCLONAL ANTIBODY; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; SCLEROSTIN; STRONTIUM RANELATE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; BONE REMODELING; BONE TURNOVER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL COMMUNICATION; COMORBIDITY; DIARRHEA; DRUG SAFETY; ENZYME ACTIVITY; ESTROGEN THERAPY; FRAGILITY FRACTURE; GERIATRIC DISORDER; HUMAN; INCIDENCE; KIDNEY FUNCTION; LONG TERM CARE; NAUSEA; OSSIFICATION; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; POLYPHARMACY; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENILE OSTEOPOROSIS; SPINE FRACTURE; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; OSTEOPOROSIS; THIOPHENES;

EID: 84884259215     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.822861     Document Type: Article

References (64)

1. WHO Study Group. Assessment of risk and its implications fracture to screening for post-menopausal osteoporosis. WHO technical report series 843 World Health Organization; Geneva, Switzerland: 1994
2. Berry SD, Samelson EJ, Hannan MT, et al. Second hip fracture in older men and women: The Framingham Study. Arch Intern Med 2007;167:1971-6
3. Tenenhouse A, Joseph L, Kreiger N, et al. Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: The Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 2000;11:897-904
4. Colon-Emeric CS, Saag KG. Osteoporotic fractures in older adults. Best Pract Res Clin Rheumatol 2006;20:695-706
5. Dempster DW. Bone microarchitecture and strength. Osteoporos Int 2003;14(Suppl5):54-6
6. Zebaze RM, Jones A, Knackstedt M, et al. Construction of the femoral neck during growth determines its strength in old age. J Bone Miner Res 2007;22:1055-61
7. Raisz LG. Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest 2005;115:3318-25
8. Chan GK, Duque G. Age-related bone loss: Old bone, new facts. Gerontology 2002;48:62-71
9. Duque G, Troen BR. Understanding the mechanisms of senile osteoporosis: New facts for a major geriatric syndrome. J Am Geriatr Soc 2008;56:935-41
10. Armas LA, Recker RR. Pathophysiology of osteoporosis: New mechanistic insights. Endocrinol Metab Clin North Am 2012;41:475-86
11. Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: An inflammatory tale. J Clin Invest 2006;116:1186-94
12. Schaffler MB, Kennedy OD. Osteocyte signaling in bone. Curr Osteoporos Rep 2012;10:118-25
13. Duque G. Bone and fat connection in aging bone. Curr Opin Rheumatol 2008;20:429-34
14. Costa AG, Cusano NE, Silva BC, et al. Cathepsin K: Its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol 2011;7:447-56
15. Roodman GD. Regulation of osteoclast differentiation. Ann NY Acad Sci 2006;1068:100-9
16. Yeung RS. The osteoprotegerin/ osteoprotegerin ligand family: Role in inflammation and bone loss. J Rheumatol 2004;31:844-6
17. Dempster DW, Lambing CL, Kostenuik PJ, Grauer A. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: A review of preclinical and clinical data. Clin Ther 2012;34:521-36
18. Cheung AM, Giangregorio L. Mechanical stimuli and bone health: What is the evidencëCurr Opin Rheumatol 2012;24:561-6
19. Chen JS, Sambrook PN. Antiresorptive therapies for osteoporosis: A clinical overview. Nat Rev Endocrinol 2011;8:81-91
20. Uihlein AV, Leder BZ. Anabolic therapies for osteoporosis. Endocrinol Metab Clin North Am 2012;41:507-25
21. Marie PJ, Felsenberg D, Brandi ML. How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int 2011;22:1659-67
22. van den Bergh JP, Bours SP, van Geel TA, et al. Optimal use of vitamin D when treating osteoporosis. Curr Osteoporos Rep 2011;9:36-42
23. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta-analysis. Lancet 2007;370:657-66
24. Bockman RS, Zapalowski C, Kiel DP, Adler RA. ASBMR Position Statement on Calcium and Cardiovascular Events. Available from: Http://www.asbmr.org/ About/detail.aspx?cid=3c1575bc-86cb- 49bf-b397-2c748fe86581 [Last accessed: 1 July 2013
25. Khosla S. Update on estrogens and the skeleton. J Clin Endocrinol Metab 2010;95:3569-77
26. de Villiers TJ, Stevenson JC. The WHI: The effect of hormone replacement therapy on fracture prevention. Climacteric 2012;15:263-6
27. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012;7:CD004143
28. Murad MH, Drake MT, Mullan RJ, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: A systematic review and network meta-analysis. J Clin Endocrinol Metab 2012;97:1871-80
29. Silverman SL, Schousboe JT, Gold DT. Oral bisphosphonate compliance and persistence: A matter of choicëOsteoporos Int 2011;22:21-6
30. Maricic M. The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol 2010;29:1079-84
31. Sambrook PN, Roux C, Devogelaer JP, et al. Bisphosphonates and glucocorticoid osteoporosis in men: Results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone 2012;50:289-95
32. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809
33. Gamsjaeger S, Buchinger B, Zwettler E, et al. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid. J Bone Miner Res 2011;26:12-18
34. Hermann AP, Abrahamsen B. The bisphosphonates: Risks and benefits of long term use. Curr Opin Pharmacol 2013;13(3):435-9
35. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis. J Bone Miner Res 2013;Epub ahead of print
36. Shane E, Ebeling PR, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research. J Bone Miner Res 2013;Epub ahead of print treated with anti-resorptives
37. Sutton EE, Riche DM. Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis. Ann Pharmacother 2012;46:1000-9
38. Miller PD. A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis 2011;3:271-82
39. Paparodis R, Buehring B, Pelley E, et al. A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract 2013;21:1-17
40. Uihlein AV, Leder BZ. Anabolic therapies for osteoporosis. Endocrinol Metab Clin North Am 2012;41:507-25
41. Canalis E. Update in new anabolic therapies for osteoporosis. J Clin Endocrinol Metab 2010;95:1496-504
42. Yu S, Burge RT, Foster SA, et al. The impact of teriparatide adherence and persistence on fracture outcomes. Osteoporos Int 2012;23:1103-13
43. Inderjeeth CA, Foo AC, Lai MM, et al. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: Review of the evidence. Bone 2009;44:744-51
44. Reginster JY, Kaufman JM, Goemaere S, et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int 2012;23:1115-22
45. Rizzoli R, Reginster JY. Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol 2011;4:593-604
46. Deal C. Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol 2009;5:20-7
47. Lewiecki EM. Monoclonal antibodies for the treatment of osteoporosis. Expert Opin Biol Ther 2013;13:183-96
48. Ng KW. Potential role of odanacatib in the treatment of osteoporosis. Clin Interv Aging 2012;7:235-47
49. Stoch SA, Zajic S, Stone JA, et al. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: Safety, tolerability, pharmacokinetics and pharmacodynamics - Results from single oral dose studies in healthy volunteers. Br J Clin Pharmacol 2012
50. Metge CJ, Leslie WD, Manness LJ, et al. Maximizing Osteoporosis Management in Manitoba Steering Committee. Postfracture care for older women: Gaps between optimal care and actual care. Can Fam Physician 2008;54:1270-6
51. Silverman S, Christiansen C. Individualizing osteoporosis therapy. Osteoporos Int 2012;23:797-809
52. Baim S, Leslie WD. Assessment of fracture risk. Curr Osteoporos Rep 2012;10:28-41
53. Mitchell PJ. Best practices in secondary fracture prevention: Fracture liaison services. Curr Osteoporos Rep 2013;11:52-60
54. Compston J. Monitoring osteoporosis treatment. Best Pract Res Clin Rheumatol 2009;23:781-8
55. Funck-Brentano T, Biver E, Chopin F, et al. Clinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring: A systematic review. Semin Arthritis Rheum 2011;41:157-69
56. Inderjeeth CA, Poland KE. Management of osteoporosis in older people. J Pharm Practi Res 2010;229-34
57. Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: An analysis of the fracture intervention trial. J Bone Miner Res 2007;22:503-8; 54
58. Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011;96:1727-36
59. Boonen S, McClung MR, Eastell R, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: Implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004;52:1832-9
60. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40
61. Masud T, McClung M, Geusens P. Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. Clin Interv Aging 2009;4:445-9
62. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22
63. Seeman E, Vellas B, Benhamou C, et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 2006;21:1113-20
64. Boonen S, Black DM, Colón-Emeric CS, et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 2010;58:292-9